Franklin Genomic Advancements Etf Beneish M Score
| HELX Etf | USD 29.86 0.33 1.12% |
Franklin |
At this time, Franklin Genomic's M Score is inapplicable. The earnings manipulation may begin if Franklin Genomic's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Franklin Genomic executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Franklin Genomic's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-4.84
Beneish M Score - Inapplicable
Did you try this?
Run Piotroski F Score Now
Piotroski F ScoreGet Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
| All Next | Launch Module |
About Franklin Genomic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Franklin Genomic Advancements's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Franklin Genomic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Franklin Genomic Advancements based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Franklin Genomic Adv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Franklin Genomic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Franklin Genomic Advancements Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Franklin Genomic Advancements Etf:Check out Franklin Genomic Piotroski F Score and Franklin Genomic Altman Z Score analysis. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
The market value of Franklin Genomic Adv is measured differently than its book value, which is the value of Franklin that is recorded on the company's balance sheet. Investors also form their own opinion of Franklin Genomic's value that differs from its market value or its book value, called intrinsic value, which is Franklin Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Franklin Genomic's market value can be influenced by many factors that don't directly affect Franklin Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Franklin Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Franklin Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Franklin Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.